Dendreon to Host Conference Call on November 2, 2011 to Announce Third Quarter 2011 Financial Results

SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (NASDAQ:DNDN) today announced that management will host a conference call on Wednesday, November 2, 2011 at 4:30 p.m. ET to review the third quarter 2011 financial results.

Access to the discussion may be obtained as follows:

Time:  

4:30 p.m. ET / 1:30 p.m. PT

Date: November 2, 2011
Dial-in:

1-877-548-9590 (domestic) or +1-720-545-0037 (international);
conference pass code: 15978924

Webcast:

www.dendreon.com (homepage and investor relations section)

 

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 15978924. The replay will be available from 7:30 p.m. ET on November 2 until 11:59 p.m. ET on November 9. In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.



CONTACT:

Dendreon Corporation
V.P. Corporate Communications & Investor Relations
Katherine Stueland, 206-829-1522

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.